ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN
 

Outsourcing

AMRI, Thermo Fisher ink vaccine service deals

by Rick Mullin
September 11, 2020 | APPEARED IN VOLUME 98, ISSUE 35

 

Albany Molecular Research Inc. (AMRI) has signed a deal to provide sterile fill-and-finish services for AstraZeneca’s COVID-19 vaccine candidate, AZD1222. AMRI will do the work at its facility in Albuquerque, New Mexico. Meanwhile, Inovio has picked Thermo Fisher Scientific to manufacture its DNA COVID-19 vaccine candidate, INO-4800. Thermo Fisher will make the active ingredient and provide fill-and-finish services at plants in the US. Both AstraZeneca and Inovio have several other production partners.

Support nonprofit science journalism
C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support us:
Donate Join Subscribe

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment